DRUG CIK: 1827401

Bright Minds Biosciences Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions CAD
FY21:
20.0
FY22:
11.9
FY23:
6.81
FY24:
5.99
FY25:
84.3
(positive)
Change from FY21 to FY25
millions CAD
FY21:
0.00
FY22:
0.14
FY23:
0.07
FY24:
0.12
FY25:
0.11
Total assets
Change from FY21 to FY25
millions CAD
FY21:
20.0
FY22:
12.1
FY23:
6.88
FY24:
6.10
FY25:
84.4

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions CAD
FY21:
0.64
FY22:
1.47
FY23:
0.28
FY24:
0.53
FY25:
2.34
(negative)
millions CAD
FY21:
0
FY22:
0.07
FY23:
0
FY24:
0.04
FY25:
0.04
(positive)
Change from FY21 to FY25
millions CAD
FY21:
19.4
FY22:
10.5
FY23:
6.60
FY24:
5.54
FY25:
82.0
Total liabilities & equity
Change from FY21 to FY25
millions CAD
FY21:
20.0
FY22:
12.1
FY23:
6.88
FY24:
6.10
FY25:
84.4

All amounts in millions CAD Data sources:SEC EDGARTwelve Data